Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization

Last updated: January 26, 2026
Sponsor: University Hospital, Brest
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Medical treatment

Surgical treatment

embolization of the MMA

Clinical Study ID

NCT05374681
29BRC22.0028
  • Ages > 18
  • All Genders

Study Summary

Chronic subdural hematomas (CSH) are collections of blood in the subdural space. CSH are becoming the most common cranial neurosurgical condition among adults, and a significant public health problem, due to an increasing use of anticoagulant and antiplatelet medication in an ageing population. Symptomatic CSH, or CSH with a significant mass effect, are treated surgically. However, recurrences are common (10 to 20%). Conservative management (medical) is used in patients who are asymptomatic or have minor symptoms. However, therapeutic failures, requiring surgical treatment, are common. The pathophysiology of CSH involves inflammation, angiogenesis, and clotting dysfunction. Self-perpetuation and rebleeding is thought to be caused by neo-membranes from the inflammatory remodeling of the dura-mater mainly fed by the distal branches of the middle meningeal artery (MMA). There are 13 ongoing registered RCTs in CSH, with the most common covering application of steroids, surgical techniques and tranexamic acid. Further to this, there are trials running on other pharmacological agents, and peri-operative management. Some industrial or academic trials are or will enroll in France in the next year in France. But to our best knowledge, none of these trials will the eventual benefits of the MMA embolization in both cases of medical and/or surgical management, and none will focus on the use of cyanoacrylates (CYA) for this purpose.

Preliminary case series and nonrandomized retrospective studies have suggested that MMA embolization alone or as adjuvant therapy to surgery can decrease recurrences.

The investigators hypothesize that in both conditions of conservative or surgical managements, endovascular embolization of patients with CSH significantly reduces the risk of recurrence of CSH. The investigators choose the CYA as liquid embolic agent because of the pain and cost of the use of Ethylen Vinyl alcohol copolymer (EVOH) agents and its simplicity to be used.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with a more than 10 mm CSH confirmed by NCCT

  • CSH localized to convexity

  • Patient aged 18 years or more at the time of the enrollment

  • Patient beneficiary from health insurance

Exclusion

Exclusion Criteria:

  • Any contraindication as required per angiogram procedure (severe renal failure ≥ 4,allergy…)

  • Pre-existing severe disability resulting in baseline mRS score > 3

  • Life expectancy of less than 6 months due to another cause than CSH

  • Patient under legal protection or deprived of liberty by a judicial oradministrative decision

  • Pregnant or breastfeeding women

  • Vulnerable persons unable to give consent

Study Design

Total Participants: 550
Treatment Group(s): 3
Primary Treatment: Medical treatment
Phase:
Study Start date:
March 28, 2023
Estimated Completion Date:
September 28, 2028

Study Description

  • Indication of surgical or conservative management will be decided by the neurosurgeon.

  • Experimental arm:

CSH requiring hematoma removal will be surgically managed with a surgical technique applied depending on the surgeon's discretion.

Medical management will be adopted according to neurosurgeons habits. MMA embolization (on the CSH side or bilaterally if necessary) in the Experimental Arms will be performed with Cyanoacrylates and preferentially using conscious sedation or local anesthesia.

• Control arm: CSH requiring hematoma removal will be surgically managed with a surgical technique applied depending on the surgeon's discretion.

Medical management will be adopted according to neurosurgeons habits

• Primary and secondary end points will be assessed at 2 months+/- 1 month and assessed at 6 +/- 2 months. The blind items will be the mRS and the RACE score. The volume of the CSH will be semi-automatically assessed using the ABC/2 method and the estimated maximal thickness of the CSH on axial images.

Connect with a study center

  • CHU Amiens-Picardie

    Amiens 3037854, France 80054
    France

    Terminated

  • CHU Brest

    Brest 3030300, France 29609
    France

    Active - Recruiting

  • CHU Caen

    Caen 3029241, France 14000
    France

    Terminated

  • Hôpital Henri Mondor

    Créteil 3022530, France 94000
    France

    Active - Recruiting

  • CHU Nantes

    Nantes 2990969, France 44000
    France

    Active - Recruiting

  • CHU Nice

    Nice 2990440, France 06000
    France

    Active - Recruiting

  • Hôpital Fondation Rothschild

    Paris 2988507, France 75019
    France

    Active - Recruiting

  • Hôpital Pitié Salpêtrière

    Paris 2988507, France 75013
    France

    Active - Recruiting

  • CHU Tours

    Tours 2972191, France 37000
    France

    Terminated

  • CHU Amiens-Picardie

    Amiens, 80054
    France

    Site Not Available

  • CHU Bordeaux

    Bordeaux, 33076
    France

    Site Not Available

  • CHU Bordeaux

    Bordeaux 3031582, 33076
    France

    Active - Recruiting

  • CHU Brest

    Brest, 29609
    France

    Site Not Available

  • CHU Caen

    Caen, 14000
    France

    Site Not Available

  • CHU Nancy

    Nancy, 54035
    France

    Site Not Available

  • CHU Nancy

    Nancy 2990999, 54035
    France

    Active - Recruiting

  • CHU Nantes

    Nantes, 44000
    France

    Site Not Available

  • Hôpital Pitié Salpêtrière

    Paris, 75013
    France

    Site Not Available

  • CHU Tours

    Tours, 37000
    France

    Site Not Available

  • CHU Martinique

    Fort-de-France, 97261
    Martinique

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.